Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CA11 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | PHLPP1 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | SRRM3 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | ACVR2B | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
mRNA | FBXL4 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | ZNF227 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
mRNA | ADAMTSL2 | CTRPv2 | pan-cancer | AAC | 0.13 | 3e-05 |
mRNA | CSNK1G2 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | ZDHHC15 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | MDN1 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |